IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.…
IRADIMED (IRMD) Shares Moved, What Is Behind The Latest Attention?
IRADIMED (NASDAQ: IRMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 166 employees.
The shares were at 81.02 USD on 20 November 2026, down 2.8% over 52 weeks. Its 52-week range is 76.35 USD to 107.90 USD: the price is 24.9% below the high and 6.1% above the low.
At a market capitalisation of 1.04B USD, it trades at 43.3 times trailing earnings and 33.3 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 70% for IRMD. It pays a dividend yielding 0.98% (it pays out 41% of its earnings), against a median of 2.35% among the dividend payers in that peer group.
IRADIMED reports return on equity of 23.8%, an operating margin of 32.3% and revenue up 14.2% year over year.
It holds more cash than debt, a net cash position of 63.29M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 2 analysts cover the stock; their mean price target of 118.00 USD is 45.6% above the current price. The next earnings report is expected on 10 February 2027.